Anti-CD47 drugs work by blocking the "do not eat me" signal that cancer cells use to evade phagocytosis by macrophages. By blocking this CD47 signal, anti-CD47 monoclonal antibodies can enable macrophage phagocytosis of tumor cells, a potentially powerful approach against a range of cancers. Anti-CD47 therapy represents a promising new class of cancer immunotherapy that may provide clinical benefits either as monotherapy or in combinations with other immunotherapies or conventional cytotoxic agents. The advantages of exploiting anti-phagocytosis pathway include broad applicability across solid and hematologic cancers as well as potential synergies with other anti-cancer agents. Given limited treatment options for many advanced cancers and the urgent need to enhance immune-based therapies, anti-CD47 drugs are poised to transform cancer treatment if ongoing clinical studies validate their promise.

The anti CD47 drugs market is estimated to be valued at USD 0.14 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 42.9% from 2024 to 2031.

The rapidly growing clinical pipeline and promising early data have fueled significant interest from big pharmaceutical companies as well as smaller biotechs, drawn by the blockbuster sales potential of a successful Anti CD47 Drugs Market. Global spending on cancer treatments is projected to nearly double to over $200 billion by 2030 creating a vast commercial opportunity. 

Get more insights on: Anti CD47 Drugs Market

Get this Report in Japanese Language: 抗CD47薬市場

Get this Report in Korean Language: 항 CD47 약물 시장